Database : HANSEN
Search on : CLOFAZIMINA [Subject descriptor]
References found : 91 [refine]
Displaying: 1 .. 20   in format [Detailed]

page 1 de 5 go to page              

  1 / 91 HANSEN  
              next record last record
select
to print
Texto Completo-en
Id:19754
Author:Katoch, Kiran; Ramu, Gopal; Ramanathan, Usha; Sengupta, Utpal; Sharma, Vishnu D; Shivannavar, Channappa T; Katoch, Vishwa M.
Title:Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
Source:Int J Lepr;57(2):451-457, June 1989. ^bgraf, ^btab.
Abstract: regimen consisting of 600 mg of rifampin once a month, 100 mg of clofazimine on alternate days, and 100 mg of dapsone daily was used in 56 untreated, highly bacillated borderline lepromatous/lepromatous (BL/LL) patients with an average bacterial index (BI) of 4.45. Treatment was continued until skin-smear negativity. After 2 years of therapy, none of the patients had become smear negative and the average BI was 2.56. There was no growth on inoculation of skin-tissue biopsies in the normal mouse foot pad after 6 months of therapy. Bacillemia was still detectable in 11/50 patients, and significant ATP levels were detected in Mycobacterium leprae from skin-tissue biopsies in 16% of the cases. After 3 years of therapy, three patients had become smear negative. The average BI was 1.30. None of the patients had detectable bacillemia, and 5% of the cases showed detectable ATP levels in M. leprae from tissue biopsies. After 4 years of therapy, 41.7% of the patients had become smear negative. The average BI was 0.66, and no ATP was detected in any of the purified bacillary suspensions. The fall in BI was accelerated, and more patients on continued treatment became negative earlier compared to those having treatment for a limited duration, as reported by others^ien.
Descriptors:Clofazimina/admin
Clofazimina/uso terap
Dapsona/admin
Dapsona/uso terap
Hanseníase Dimorfa/microbiol
Hanseníase Virchowiana/microbiol
Limits:Humanos
Adolescente
Adulto
Electronic Medium:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a01.pdf / en
Location:Br191.1


  2 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:18390
Author:Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K
Title:Drug resistant-Mycobacterium leprae- results of mouse footpad studies from a laboratory in South India ..-
Source:s.l; s.n; 2002. 12 p. tab.
Abstract:Out of 265 biopsies of leprosy patients received at the Experimental Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae using the mouse footpad technique, 49 showed resistant strains of M. leprae to varying concentration of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resitance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistent strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emplasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community (AU).
Descriptors:MYCOBACTERIUM LEPRAE/cresc
MYCOBACTERIUM LEPRAE/isol
MYCOBACTERIUM LEPRAE/metab
MYCOBACTERIUM LEPRAE/patogen
MYCOBACTERIUM LEPRAE/ultraest
RESISTÊNCIA A DROGAS
DAPSONA/uso terap
CLOFAZIMINA/uso terap
RIFAMPINA/uso terap
TESTES DE SENSIBILIDADE MICROBIANA/métodos
TESTES DE SENSIBILIDADE MICROBIANA/vet
HANSENIASE/clas
 HANSENIASE/compl
 HANSENIASE/quimioter
 HANSENIASE/imunol
 HANSENIASE/microbiol
 HANSENIASE/patol
 OFLOXACINO/uso terap
 MINOCICLINA/uso terap
Limits:HUMANO
Location:BR191.1; 09299/s


  3 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:18385
Author:Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong
Title:Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice ..-
Source:s.l; s.n; 2000. 3 p. tab.
Abstract:Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP. Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slighthy more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae (AU).
Descriptors:HANSENIASE/quimioter
HANSENOSTATICOS/admin
HANSENOSTATICOS/farmacol
HANSENOSTATICOS/farmacocin
HANSENOSTATICOS/uso terap
MYCOBACTERIUM LEPRAE
TESTES DE SENSIBILIDADE MICROBIANA/métodos
DROGAS EM INVESTIGACAO/admin
DROGAS EM INVESTIGACAO/anal
DROGAS EM INVESTIGACAO/uso terap
BACTERICIDAS
 QUIMIOTERAPIA COMBINADA
 MYCOBACTERIUM LEPRAE/metab
 MYCOBACTERIUM LEPRAE/fisiol
 DAPSONA/uso terap
 RIFAMPINA/uso terap
 CLOFAZIMINA/uso terap
 OFLOXACINO/uso terap
 MINOCICLINA/uso terap
 CLARITROMICINA/uso terap
Limits:ESTUDO COMPARATIVO
Location:BR191.1; 09311/s


  4 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:18384
Author:Biswas, S; Mondal, K. K
Title:Multidrug therapy in leprosy can prevent relapse- a retrospective study ..-
Source:s.l; s.n; 2002. 6 p. .
Abstract:A retrospective study was done at the Leprosy Control Unit (LCU) in Durgapur of Burdwan district, West Bengal, to determine the relapse rate following multidrug therapy (MDT). A total of 1581 patients (1276 PB and 305 MB) completed MDT regimens during a period of 5 years as per WHO recommendations and National Leprosy Eradication Programme (NLEP) guidelines. The treated patients were kept under surveillance as per NLEP guidelines and searched for relapses. The results of MDT were compared with those of pre-MDT (monotherapy) era at the same centre (total: 405 patients; PB-373, MB-32) andalso with those of the Leprosy Clinic in Gopalpur (only dapsone was given to a total of 189 patients, PB-167, MB-22) Following monotherapy, the relapse rate was 10.06% at the Gopalpur Leprosy Clinic and 12.4% at the Dargapur LCU during the 2 years (PB) and 5 years (MB) of surveillance, whereas following MDT no relapse case was encountered both in PB and MB cases during the surveillance periods recommended by WHO. The results of this study are comparable with those of ohter studies. Though a few studies showed relapses during long-term surveillance beyond the periods recommended by WHO, it is once again established that MDT can prevent relapse in leprosy (AU).
Descriptors:HANSENIASE/quimioter
HANSENIASE/epidemiol
HANSENIASE/prev
RECIDIVA/prev
HANSENOSTATICOS/admin
 HANSENOSTATICOS/hist
 HANSENOSTATICOS/normas
 HANSENOSTATICOS/uso terap
 CLOFAZIMINA/uso terap
 DAPSONA/uso terap
 RIFAMPINA/uso terap
Limits:ESTUDO COMPARATIVO
HUMANO
Location:BR191.1; 09310/s


  5 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:18294
Author:Wood, Leonard
Title:A statistical analysis of two chemotherapy trials in lepromatous leprosy: I- The response to therapy as measured by inoculation of mice ..-
Source:s.l; s.n; 1978. 10 p. tab.
Abstract:Two recent trials of chemotherapy in relatively large numbers of patients with lepromatous leprosy generated data that permitted analysis of the effects of treatment regimens and of various pretreatment characteristics of the patients. The results of treatment were measured by inoculation of mice with Mycobacterium leprae recovered from skin biopsy specimens obtained from the patients at intervals during the trials. The pretreatment variables-sex, age histopathological and clinical classifications, logarithmic biopsy specimen (LAFB) - were found to be uniformly distributed among the 36 patients treated by regimens 1, 2, 4 and 5 of trial I. . The ten patients treated by regimen 3 were excluded from this analysis. These pretreatment variables were also found to be uniformly distributed among all 21 patients treated by the two regimens of trial II...(AU).
Descriptors:HANSENIASE VIRCHOWIANA/clas
HANSENIASE VIRCHOWIANA/quimioter
HANSENIASE VIRCHOWIANA/fisiopatol
DAPSONA/uso terap
RIFAMPINA/uso terap
CLOFAZIMINA/uso terap
Limits:ESTUDO COMPARATIVO
Location:BR191.1; 0296/S


  6 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:18229
Author:Leonard Wood Memorial*.
Title:A statistical analysis of two chemotherapy trials in lepromatous leprosy: II. Interactions among patient variables ..-
Source:s.l; s.n; 1978. 4 p. tab.
Abstract:Interrelationship among six patient characteristics recorded upon entry the trial were analyzed for 67 patients with lepromatous and near-lepromatous leproay admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of older patients and of patients classified as borderline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological grounds were classified fully lepromatous by the clinical criteria. Measurments of the number of Mycobacterium leprae in the patients made by there methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the hand, and any of the measurments of the numbers of organisms on the other (AU).
Descriptors:HANSENIASE DIMORFA/terap
HANSENIASE VIRCHOWIANA/terap
CLOFAZIMINA/admin
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
RIFAMPINA/uso terap
DAPSONA/uso terap
HANSENIASE DIMORFA/microbiol
HANSENIASE DIMORFA/patol
HANSENIASE VIRCHOWIANA/microbiol
HANSENIASE VIRCHOWIANA/patol
QUIMIOTERAPIA COMBINADA
 DROGAS EM INVESTIGACAO/admin
 DROGAS EM INVESTIGACAO/uso terap
Limits:ESTUDO COMPARATIVO
HUMANO
Location:BR191.1; 00294/s


  7 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:18225
Author:Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K
Title:Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India ..-
Source:s.l; s.n; 2002. 12 p. tab.
Abstract:Out of 265 biopsies of leprosy patients received at the Experimental Pathology Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae, using the mouse footpad technique, 49 showed resistant strains of M leprae to varying concentrations of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resistance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistant strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emphasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community. (AU).
Descriptors:Clofazimina/PD
Dapsona/PD
Farmacorresistência Bacteriana
Farmacorresistência Bacteriana Múltipla
Índia
Hansenostáticos/*PD
Hanseníase/*DT/MI
Camundongos
Camundongos Endogâmicos CBA
Testes de Sensibilidade Microbiana
Mycobacterium leprae/*DE
Rifampina/PD
Limits:HUMANO
ANIMAL
MASCULINO
FEMININO
Location:BR191.1; 09179/S


  8 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:18090
Author:Sampaio, Sebastiao AP; Rivitti, Evandro A.
Title:Hanseníase / Leprosy
Source:In: Sampaio, Sebastiao AP; Rivitti, Evandro A.Dermatologia. Sao Paulo, Artes Medicas, 2007. p.625-651ilus, graf.
Descriptors:HANSENIASE/imunol
HANSENIASE/microbiol
HANSENIASE/prev
HANSENIASE/fisiopatol
HANSENIASE/reabil
HANSENIASE/terap
MYCOBACTERIUM LEPRAE/citol
MYCOBACTERIUM LEPRAE/genet
MYCOBACTERIUM LEPRAE/imunol
MYCOBACTERIUM LEPRAE/fisiol
ANTIGENO DE MITSUDA/quim
ANTIGENO DE MITSUDA/fisiol
RIFAMPINA/farmacol
 RIFAMPINA/uso terap
 DAPSONA/farmacol
 DAPSONA/uso terap
 CLOFAZIMINA/farmacol
 CLOFAZIMINA/uso terap
Limits:ESTUDO COMPARATIVO
HUMANO
Location:Br191.1; WR100, S47d


  9 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:17961
Author:World Health Organization.
Title:Leprosy.
Source:In: World Health Organization.Tropical diseases: progress in international research, 1987-1988. s.l, s.n, 1989. p.93-100ilus, graf.
Descriptors:HANSENIASE/compl
HANSENIASE/diag
HANSENIASE/quimioter
HANSENIASE/imunol
HANSENIASE/fisiopatol
HANSENIASE/terap
MYCOBACTERIUM LEPRAE/imunol
MYCOBACTERIUM LEPRAE/fisiol
RIFAMPINA/sint quim
RIFAMPINA/imunol
DAPSONA/sint quim
 DAPSONA/imunol
 CLOFAZIMINA/quim
 CLOFAZIMINA/imunol
Limits:ESTUDO COMPARATIVO
HUMANO
Location:BR191.1. aWC680, O14t


  10 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:17453
Author:Wood, L
Title:A statistical analysis of two chemotherapy trials in lepromatous leprosy ?-
Source:s.l; s.n; 1978. 4p p. .
Abstract:Interrelationships among six patient characteristics recorded upon entry into the trial were analyzed for 67 patients with lepromatous and near-lepromatous leprosy admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of other patients and of patients classified as bordeline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological ground were classified fully lepromatous by the clinical criteria. Measurementd of the number of Mycobacterium leprae in the patients made by three methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the one hand, and any of the measurements of the numbers of organisms on the other.
Descriptors:HANSENIASE VIRCHOWIANA/clas
HANSENIASE VIRCHOWIANA/quimioter
HANSENIASE VIRCHOWIANA/microbiol
HANSENIASE VIRCHOWIANA/patol
DAPSONA/uso terap
RIFAMPINA/uso terap
CLOFAZIMINA/uso terap
Limits:RELATO DE CASO
Location:BR191.1; 00294/s; BR191.1; 00295/s


  11 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:17389
Author:Avelleira, Joao Carlos Regazzi.
Title:Tratamento da hanseniase / ?
Source:In: Rio de Janeiro (Estado). Secretaria da Saude.Curupaiti em Revista. Rio de Janeiro, s.n, 2002. p.24-27ilus.
Abstract:O controle da hanseniase e considerado uma das prioridades da OMS, por ser uma endemia com potencial incapacitante importante. Os autores fazem uma revisao do tratamento da hanseniase desde a utilizacao do oleo de chaulmugra em 1854, passando pela introducao da sulfona em 1941, ao aparecimento da resistencia secundaria e primaria a sulfona, razao da associacao de outras drogas no tratamento da doenca. O esquema dividia os pacientes em multibacilares e paucibacilares, usando regimes com tres drogas (Rifampicina, Clofazimina e Dapsona) para as formas multibacilares e duas drogas (Rifampicina e Sulfona) para os paucibacilares. Foram realizadas mudancas na duracao do tratamento, e novas drogas como as quinolonas, claritromicina e minociclina mostraram eficacia contra o M. leprae possam ser utilizadas em esquemas alternativos. (AU).
Descriptors:HANSENIASE/prev
TERAPÊUTICA
DAPSONA/uso terap
RIFAMPINA/uso terap
CLOFAZIMINA/uso terap
Limits:RELATO DE CASO
Location:BR191.1; 01114/d.a


  12 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:17303
Author:Queiroz, R. H. C; Pereira, R. C; Gotardo, M. A; Cordeiro, D. S; Melchior, E
Title:Determination of clofazimine in leprosy patients by high-performance liquid chromatography ..-
Source:s.l; s.n; 2003. 4 p. ilus, tab.
Abstract:An original, simple, specific, and rapid high-performance liquid chromatography assay for the determination of clofazimine in human plasma is presented. The procedure consists of extracting the drug and the internal standard (medazepam) from 0.5 mL plasma with dichloromethane/diisopropyl ether (1:1, v/v) at pH 3.0, after precipitating the proteins with methanol. The drugs were then quantitated on a reversed-phase C8 using a mobile phase consisting of a mixture of methanol/0.25 N sodium acetate buffer at pH 3.0 (74:26, v/v). The flow-rate and wavelength were set at 1 mL/min and 286 nm, respectively. The precision, linearity, and limit of quantitation of the method were within acceptable limits. The method was considered adequate and could be applied in studies involving blood level monitoring and pharmacokinetics in leprosy patients. (AU).
Descriptors:Cromatografia Líquida de Alta Pressão/*MT
Clofazimina/*PK/TU
Monitoramento de Medicamentos/*MT
Hansenostáticos/*PK/TU
Hanseníase/DT/*ME
Reprodutibilidade de Resultados
Sensibilidade e Especificidade
Limits:Feminino
Humano
Masculino
Location:BR191.1; 01158/s


  13 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:15629
Author:Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat
Title:Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages ..-
Source:s.l; s.n; 2003. 10 p. graf.
Abstract:Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU).
Descriptors:ANTIINFECCIOSOS/quim
ANTIINFECCIOSOS/farmacol
ANTIINFECCIOSOS/tox
CELULAS CULTIVADAS
CLOFAZIMINA/quim
CLOFAZIMINA/farmacol
CLOFAZIMINA/tox
MACROFAGOS/ef drogas
TESTES DE SENSIBILIDADE MICROBIANA
COMPLEXO MYCOBACTERIUM AVIUM/ef drogas
ESTEROIS/quim
ACIDO SUCCINICO
Limits:ESTUDO COMPARATIVO
HUMANO
ANIMAL
CAMUNDONGOS
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 09082/s


  14 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:15627
Author:Kaluarachchi, S. I; Fernandopulle, B. M. R; Gunawardane, B. P
Title:Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study ..-
Source:s.l; s.n; 2001. 9 p. tab.
Abstract:This study analyses retrospectively some of the risks associated with the use of WHO-multidrug therapy (MDT) in Sri Lanka. Case records of 3,333 new cases of leprosy attending the Central Leprosy Clinic in Colombo during 1991-1995, were analysed for adverse drug reactions involving the liver and blood. There were 81 reports of suspected hepatic or haematological adverse reactions associated with the use of MDT, of which 39 were classified as haemolytic anaemia, 25 as toxic hepatitis, 2 as methaemoglobinaemia and 15 as anaemia. Dapsone, was incriminated in the majority of adverse reactions (72 per cent). Adverse drug reactions were more common in female than male subjects (55 per cent vs 45 per cent; P < 0.5), but there was no significant differences between the age groups. Majority of adverse reactions was seen within the first three months of initiation of MDT. This study in no way undermines the benefits of MDT but highlights the risks and suggests measures to minimize these risks. (AU).
Descriptors:ANEMIA/ind quim
ANEMIA/epidemiol
CLOFAZIMINA/ef adv
DAPSONA/ef adv
QUIMIOTERAPIA COMBINADA
HEPATITE TOXICA/epidemiol
HANSENOSTATICOS/ef adv
HANSENOSTATICOS/uso terap
HANSENIASE/quimioter
ESTUDOS RETROSPECTIVOS
RIFAMPINA/ef adv
RIFAMPINA/uso terap
METEMOGLOBINEMIA/ind quim
METEMOGLOBINEMIA/epidemiol
Limits:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
MEIA-IDADE
ADOLESCENTE
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 09163/s


  15 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:13969
Author:Salafia, A; Ghauhan, G.
Title:Clofazimine crystals and ceroid bodies in nerve: a case report.
Source:Fontilles - Revista de Leprología;19(1):73-76, Ene.-Abr. 1993. .
Abstract:Clofazimina in one of the most widely used in leprosy bacause of its anti-bacteriostatic and anti-inflammatory activit deposition of clofaznine has been reported in various organs and body tissues, however, the authors think the deposition of clofazinime crystals in nerve tissue, as fas as we know has never been reported. (AU).
Descriptors:CLOFAZIMINA
CEROIDE
CLOFAZIMINA/admin
Limits:RELATO DE CASO
Location:BR191.1


  16 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:13945
Author:Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat
Title:Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages ..-
Source:s.l; s.n; 2003. 10 p. graf.
Abstract:Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU).
Descriptors:ANTIINFECCIOSOS/quim
ANTIINFECCIOSOS/farmacol
ANTIINFECCIOSOS/tox
CLOFAZIMINA/quim
CLOFAZIMINA/farmacol
CLOFAZIMINA/tox
CELULAS CULTIVADAS
MACROFAGOS/ef drogas
MACROFAGOS/microbiol
TESTES DE SENSIBILIDADE MICROBIANA
COMPLEXO MYCOBACTERIUM AVIUM/ef drogas
ESTEROIS/quim
ACIDO SUCCINICO/quim
Limits:ESTUDO COMPARATIVO
HUMANO
ANIMAL
CAMUNDONGOS
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 09082/s


  17 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:13943
Author:Murray, Clinton K; Joyce, M. Patricia; Longfield, Robert N
Title:Short report: treatment failure in Hanse´n's disease ..-
Source:s.l; s.n; 2003. 2 p. tab.
Abstract:Areas of low endemicity of Hansen's disease, such as Texas, California, and Hawaii, exist due to immigration and rare autochthonous infections. Managing this disease in these areas of low endemicity is difficult, especially in observing for relapse. The accurate diagnosis of relapse is imperative so that appropriate therapy can be promptly reinstituted and unnecessary treatment can be avoided. To assess treatment failures in an area of low endemicity, we retrospectively evaluated 113 patients with Hansen's disease treated in southern Texas. Of 57 patients who completed therapy, 11 were later restarted on medications for this disease for presumed relapse. However, nine of the 11 were found not to have true relapses of Hansen's disease. The accurate diagnosis of relapse of this disease is essential not only in the individual patient but also for prospective treatment trials to establish best practices. (AU).
Descriptors:CLOFAZIMINA/admin
DAPSONA/admin
QUIMIOTERAPIA COMBINADA
HANSENIASE/quimioter
HANSENIASE/epidemiol
HANSENIASE/patol
HANSENIASE/prev
REGISTROS MEDICOS
RECIDIVA
ESTUDOS RETROSPECTIVOS
RIFAMPINA/admin
TEXAS/epidemiol
FALHA DE TRATAMENTO
RECUSA DO PACIENTE AO TRATAMENTO
Limits:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
MEIA-IDADE
IDOSO
ADOLESCENTE
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 09084/s


  18 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:13718
Author:Siccoli, M; Bassetti, C
Title:Wie lautet Ihre Diagnose? Senso-motorische Polyneuropathie bei Lepra, Borderline-Form. Trophische Hautstörungen mit Ulzerationen, lokale Superinfektion am rechten Fuss mit inguinaler Lymphoadenopathie rechts What is your diagnosis? Sensory motor polyneuropathy in borderline leprosy. Trophic skin disorders with ulcerations, local superinfection on the right foot with right inguinal lymphadenopathy-
Source:s.l; s.n; 2002. 4 p. ilus.
Descriptors:CLOFAZIMINA/AD/TU
DAPSONA/AD/TU
DIAGNOSTICO DIFERENCIAL
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/AD/TU
HANSENIASE DIMORFA/*DI/DT
RIFAMPINA/AD/TU
FATORES DE TEMPO
Limits:ADOLESCENTE
RELATO DE CASO
HUMANO
MASCULINO
Location:BR191.1; 09062/s


  19 / 91 HANSEN  
              first record previous record next record last record
select
to print
Id:13655
Author:Kaluarachchi, S. I; Fernandopulle, B. M. R; Gunawardane, B. P
Title:Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study ..-
Source:s.l; s.n; 2001. 9 p. tab.
Abstract:This study analyses retrospectively some of the risks associated with the use of WHO-multidrug therapy (MDT) in Sri Lanka. Case records of 3,333 new cases of leprosy attending the Central Leprosy Clinic in Colombo during 1991-1995, were analysed for adverse drug reactions involving the liver and blood. There were 81 reports of suspected hepatic or haematological adverse reactions associated with the use of MDT, of which 39 were classified as haemolytic anaemia, 25 as toxic hepatitis, 2 as methaemoglobinaemia and 15 as anaemia. Dapsone, was incriminated in the majority of adverse reactions (72 per cent). Adverse drug reactions were more common in female than male subjects (55 per cent vs 45 per cent; P < 0.5), but there was no significant differences between the age groups. Majority of adverse reactions was seen within the first three months of initiation of MDT. This study in no way undermines the benefits of MDT but highlights the risks and suggests measures to minimize these risks. (AU).
Descriptors:ANEMIA/ind quim
ANEMIA/epidemiol
CLOFAZIMINA/ef adv
DAPSONA/ef adv
QUIMIOTERAPIA COMBINADA
HEPATITE TOXICA/epidemiol
HANSENOSTATICOS/ef adv
HANSENOSTATICOS/uso terap
HANSENIASE/quimioter
METEMOGLOBINEMIA/ind quim
METEMOGLOBINEMIA/epidemiol
ESTUDOS RETROSPECTIVOS
RIFAMPINA/ef adv
RIFAMPINA/uso terap
Limits:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
ADOLESCENTE
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 09123/s


  20 / 91 HANSEN  
              first record previous record
select
to print
Id:13641
Author:Goulart, Isabela Maria Bernades; Arbex, Guilherme Leonel; Carneiro, Marcus Hubaide; Rodrigues, Mariana Scalia; Gadia, Rafael
Title:Efeitos adversos da poliquimioterapia em pacientes com hanseníase: um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia-
Source:s.l; s.n; set.-out. 2002. 8 p. tab.
Abstract:The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlandia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7 per cent) were related to dapsone, 7 (6.2 per cent) were caused by rifampicin and 26 (20.5 per cent) were attributed to clofazimine. These effects induced 28 (14.9 per cent), patients to change the therapeutic scheme, representing 39.4 per cent from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem. (AU).
Descriptors:CLOFAZIMINA/admin
CLOFAZIMINA/ef adv
DAPSONA/admin
DAPSONA/ef adv
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENIASE/quimioter
COOPERACAO DO PACIENTE/estatíst
DESISTÊNCIA DO PACIENTE/estatíst
ESTUDOS RETROSPECTIVOS
RIFAMPINA/admin
RIFAMPINA/ef adv
Limits:PRÉ-ESCOLAR
CRIANÇA
ADOLESCENCIA
ADULTO
RESUMO EM INGLES
FEMININO
HUMANO
LACTENTE
RECEM-NASCIDO
MASCULINO
MEIA-IDADE
Location:BR191.1; 09017/s



page 1 de 5 go to page              
   


Refine the search
  Database : HANSEN Advanced form   
Search for : Free form   

    Search in field  
1  
2
3
 
           



Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO
Latin American and Caribbean Center on Health Sciences Information